• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[2020年欧洲心脏病学会指南:非持续性ST段抬高型急性冠状动脉综合征:有哪些新内容?]

[ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?].

作者信息

Thiele Holger, Jobs Alexander

机构信息

Klinik für Innere Medizin/Kardiologie, Herzzentrum Leipzig - Universität Leipzig, Strümpellstr. 39, 04289, Leipzig, Deutschland.

出版信息

Herz. 2021 Feb;46(1):3-13. doi: 10.1007/s00059-020-05002-1.

DOI:10.1007/s00059-020-05002-1
PMID:33236199
Abstract

The European Society of Cardiology (ESC) guidelines for the management of acute coronary syndrome without persistent ST-segment elevation (NSTE-ACS) published in August 2020, replace the former NSTE-ACS guidelines published in 2015. These updated guidelines have some relevant changes for the clinical practice, which include the diagnostic work-up, risk stratification, antithrombotic therapy, invasive or noninvasive coronary diagnostics and also long-term treatment. New sections deal with spontaneous coronary artery dissection (SCAD), myocardial infarction with nonobstructive coronary arteries (MINOCA) and also newly introduced quality indicators for NSTE-ACS treatment. The diagnostic work-up using highly sensitive cardiac troponin (hs-cTn) assays is emphasized with the recommendation to use fast triage decisions that enable an early rule-in (no STEMI) or rule-out (NSTEMI probable) in the emergency room or chest pain unit. In antiplatelet therapy a greater individualization of the treatment concept is recommended based on the individual ischemic/thrombotic events and bleeding complications. Some new aspects were introduced for timing of invasive coronary angiography; however, principally the very high-risk group should still immediately undergo coronary angiography and the high-risk group should undergo an invasive angiography within 24 h. In risk stratification, the former intermediate risk group has been removed, instead it is now emphasized that low-risk patients should be treated similarly to patients with chronic coronary syndrome.

摘要

欧洲心脏病学会(ESC)于2020年8月发布的非持续性ST段抬高型急性冠状动脉综合征(NSTE-ACS)管理指南取代了2015年发布的前版NSTE-ACS指南。这些更新后的指南在临床实践方面有一些相关变化,包括诊断检查、风险分层、抗栓治疗、有创或无创冠状动脉诊断以及长期治疗。新增章节涉及自发性冠状动脉夹层(SCAD)、非阻塞性冠状动脉心肌梗死(MINOCA)以及新引入的NSTE-ACS治疗质量指标。强调使用高敏心肌肌钙蛋白(hs-cTn)检测进行诊断检查,并建议采用快速分诊决策,以便在急诊室或胸痛单元早期确诊(非ST段抬高型心肌梗死)或排除(可能为NSTE-ACS)。在抗血小板治疗方面,建议根据个体缺血/血栓形成事件和出血并发症对治疗方案进行更大程度的个体化。在有创冠状动脉造影的时机方面引入了一些新内容;然而,原则上,极高危组仍应立即接受冠状动脉造影,高危组应在24小时内接受有创血管造影。在风险分层方面,原中间风险组已被取消,取而代之的是强调低危患者应与慢性冠状动脉综合征患者接受相似的治疗。

相似文献

1
[ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?].[2020年欧洲心脏病学会指南:非持续性ST段抬高型急性冠状动脉综合征:有哪些新内容?]
Herz. 2021 Feb;46(1):3-13. doi: 10.1007/s00059-020-05002-1.
2
[Management of acute coronary syndrome without ST-segment elevation].非ST段抬高型急性冠状动脉综合征的管理
Herz. 2022 Aug;47(4):381-392. doi: 10.1007/s00059-022-05120-y. Epub 2022 Jun 14.
3
Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies.急诊科非ST段抬高型急性冠状动脉综合征的处理:风险分层与治疗策略
Hosp Pract (1995). 2010 Apr;38(2):40-9.
4
Survey of clinical practice pattern in Germany's certified chest pain units : Adherence to the European Society of Cardiology guidelines on non-ST-segment elevation acute coronary syndrome.德国认证胸痛单元临床实践模式调查:对欧洲心脏病学会非 ST 段抬高型急性冠状动脉综合征指南的遵循情况。
Herz. 2022 Dec;47(6):543-552. doi: 10.1007/s00059-021-05079-2. Epub 2021 Nov 9.
5
Contemporary NSTEMI management: the role of the hospitalist.当代非ST段抬高型心肌梗死的管理:住院医师的作用。
Hosp Pract (1995). 2020 Feb;48(1):1-11. doi: 10.1080/21548331.2020.1701329. Epub 2020 Feb 20.
6
API expert consensus document on management of ischemic heart disease.缺血性心脏病管理的API专家共识文件
J Assoc Physicians India. 2006 Jun;54:469-80.
7
Invasive Management Strategies and Antithrombotic Treatments in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome in China: Findings From the Improving CCC Project (Care for Cardiovascular Disease in China).中国非 ST 段抬高型急性冠状动脉综合征患者的有创管理策略和抗血栓治疗:来自改善 CCC 项目(关爱中国心血管疾病)的研究结果。
Circ Cardiovasc Interv. 2017 Jun;10(6). doi: 10.1161/CIRCINTERVENTIONS.116.004750.
8
[ESC guidelines 2015. Non-ST-elevation acute coronary syndrome].[2015年欧洲心脏病学会指南。非ST段抬高型急性冠状动脉综合征]
Herz. 2015 Dec;40(8):1027-33. doi: 10.1007/s00059-015-4369-1.
9
Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation.2020年欧洲心脏病学会(ESC)与2015年ESC及2014年美国心脏病学会(ACC)/美国心脏协会(AHA)关于非持续性ST段抬高型急性冠状动脉综合征患者管理指南的差异。
Curr Atheroscler Rep. 2021 Oct 21;23(12):77. doi: 10.1007/s11883-021-00976-7.
10
[Management of acute coronary syndrome : ESC guidelines 2023].[急性冠状动脉综合征的管理:2023年欧洲心脏病学会指南]
Herz. 2024 Feb;49(1):5-14. doi: 10.1007/s00059-023-05222-1. Epub 2023 Nov 30.

引用本文的文献

1
Effect of ticagrelor combined with metoprolol extended-release tablets on cardiac function and clinical prognosis in elderly patients with acute coronary syndrome after percutaneous coronary intervention.替格瑞洛联合美托洛尔缓释片对老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后心功能及临床预后的影响
Front Cardiovasc Med. 2025 Jan 28;12:1492569. doi: 10.3389/fcvm.2025.1492569. eCollection 2025.
2
Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative.复方 L-36,一种 6H-1,3,4-噻二嗪衍生物的抗血小板和抗血栓形成特性。
Bull Exp Biol Med. 2024 May;177(1):63-67. doi: 10.1007/s10517-024-06132-w. Epub 2024 Jul 2.
3

本文引用的文献

1
Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment: primum non nocere!从2020年欧洲心脏病学会(ESC)非ST段抬高型急性冠状动脉综合征新指南中学到的经验:当临床判断先于并超越微弱推荐时。2020年非ST段抬高型急性冠状动脉综合征预处理指南:首要的是不伤害!
Eur Heart J. 2021 Jul 8;42(26):2607-2608. doi: 10.1093/eurheartj/ehaa861.
2
Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.经皮冠状动脉介入治疗前使用 P2Y12 受体拮抗剂与非 ST 段抬高型急性冠状动脉综合征患者预后的关系。
JAMA Netw Open. 2020 Oct 1;3(10):e2018735. doi: 10.1001/jamanetworkopen.2020.18735.
3
Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury.
治疗心肌缺血再灌注损伤的治疗性肽
Front Cardiovasc Med. 2022 Feb 17;9:792885. doi: 10.3389/fcvm.2022.792885. eCollection 2022.
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.经皮冠状动脉介入治疗和药物洗脱支架置入术后双联抗血小板治疗:系统评价和网络荟萃分析。
Circulation. 2020 Oct 13;142(15):1425-1436. doi: 10.1161/CIRCULATIONAHA.120.046308. Epub 2020 Aug 3.
4
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients.当代经皮冠状动脉介入治疗患者中学术研究联盟高出血风险定义的验证。
J Am Coll Cardiol. 2020 Jun 2;75(21):2711-2722. doi: 10.1016/j.jacc.2020.03.070.
5
Multivessel versus culprit-only PCI in STEMI patients with multivessel disease: meta-analysis of randomized controlled trials.多支血管病变的 ST 段抬高型心肌梗死患者行多支血管与罪犯血管血运重建的随机对照试验的荟萃分析。
Clin Res Cardiol. 2020 Nov;109(11):1381-1391. doi: 10.1007/s00392-020-01637-6. Epub 2020 Apr 1.
6
Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores.验证学术研究协作组高出血风险(ARC-HBR)标准在经皮冠状动脉介入治疗患者中的应用,并与当代出血风险评分进行比较。
EuroIntervention. 2020 Aug 28;16(5):371-379. doi: 10.4244/EIJ-D-20-00052.
7
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.经皮冠状动脉介入治疗后心房颤动患者双联与三联抗栓治疗的安全性和疗效结局:基于非维生素 K 拮抗剂口服抗凝剂的随机临床试验的系统评价和荟萃分析。
Eur Heart J. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732.
8
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.依度沙班与维生素 K 拮抗剂在房颤患者成功经皮冠状动脉介入治疗后抗栓治疗方案的比较(ENTRUST-AF PCI):一项随机、开放标签、3b 期临床试验。
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
9
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.替格瑞洛或普拉格雷在急性冠状动脉综合征患者中的应用。
N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.
10
Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.双联或三联抗栓治疗患者的出血和缺血结局:系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):226-236. doi: 10.1093/ehjcvp/pvz021.